Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for Alzheimer’s disease

Michela Marcatti1 · Anna Fracassi1 · Mauro Montalbano1 · Chandramouli Natarajan1 · Balaji Krishnan1 · Rakez Kayed1 · Giulio Taglialatela1

Received: 27 December 2021 / Revised: 8 March 2022 / Accepted: 17 March 2022 / Published online: 4 April 2022
© The Author(s) 2022

Abstract
Background Alzheimer’s disease (AD) is characterized by progressive cognitive decline due to accumulating synaptic insults by toxic oligomers of amyloid beta (AβO) and tau (TauO). There is growing consensus that preventing these oligomers from interacting with synapses might be an effective approach to treat AD. However, recent clinical trial failures suggest low effectiveness of targeting Aβ in late-stage AD. Researchers have redirected their attention toward TauO as the levels of this species increase later in disease pathogenesis. Here we show that AβO and TauO differentially target synapses and affect each other’s binding dynamics.

Methods Binding of labeled, pre-formed Aβ and tau oligomers onto synaptosomes isolated from the hippocampus and frontal cortex of mouse and postmortem cognitively intact elderly human brains was evaluated using flow-cytometry and western blot analyses. Binding of labeled, pre-formed Aβ and tau oligomers onto mouse primary neurons was assessed using immunofluorescence assay. The synaptic dysfunction was measured by fluorescence analysis of single-synapse long-term potentiation (FASS-LTP) assay.

Results We demonstrated that higher TauO concentrations effectively outcompete AβO and become the prevailing synaptic-associated species. Conversely, high concentrations of AβO facilitate synaptic TauO recruitment. Immunofluorescence analyses of mouse primary cortical neurons confirmed differential synaptic binding dynamics of AβO and TauO. Moreover, in vivo experiments using old 3xTgAD mice ICV injected with either AβO or TauO fully supported these findings. Consistent with these observations, FASS-LTP analyses demonstrated that TauO-induced suppression of chemical LTP was exacerbated by AβO. Finally, predigestion with proteinase K abolished the ability of TauO to compete off AβO without affecting the ability of high AβO levels to increase synaptic TauO recruitment. Thus, unlike AβO, TauO effects on synaptosomes are hampered by the absence of protein substrate in the membrane.

Conclusions These results introduce the concept that TauO become the main synaptotoxic species at late AD, thus supporting the hypothesis that TauO may be the most effective therapeutic target for clinically manifest AD.

Keywords Amyloid · Tau · Synaptic binding · Synaptosomes · Dementia
Abbreviations

| Abbreviation | Definition |
|--------------|------------|
| aCSF         | Artificial cerebrospinal fluid |
| ACTB         | Actin |
| AD           | Alzheimer’s disease |
| AβO          | Amyloid β oligomers |
| BSA          | Bovine serum albumin |
| AMPARs       | α-Amino-3-hydroxy-5-methyl-4-isoxazolopionic acid receptors |
| CERAD        | Consortium to establish a registry of AD |
| FASS-LTP     | Fluorescence analysis of single-synapse long-term potentiation |
| FC           | Frontal cortex |
| HBK          | HEPES buffered Krebs-like |
| HFP          | 1,1,1,3,3,3-Hexafluoro-2-propanol |
| NMDG         | N-Methyl-D-glucamine |
| HP           | Hippocampus |
| ICV          | Intracerebroventricular |
| MAP2         | Microtubule-associated protein 2 |
| NMDAR        | N-Methyl D-aspartate receptor |
| Nrx1β        | Neurexin-1β |
| PBS          | Phosphate-buffered saline |
| PBST         | Phosphate-buffered saline with tween |
| PFA          | Paraformaldehyde |
| PK           | Proteinase K |
| PSD95        | Postsynaptic density |
| RIPA         | Radioimmunoprecipitation assay buffer |
| SYPH         | Synaptophysin |
| TauO         | Tau oligomers |
| TBST         | Tris-buffered saline solution with tween |

Introduction

Alzheimer's disease (AD) is the most common age-related neurodegenerative disorder, clinically characterized by progressive cognitive decline and memory dysfunction [1]. The histopathologic hallmarks of AD are extracellular plaques of insoluble fibrillar aggregates of the amyloid beta peptide (Aβ) and intracellular neurofibrillary tangles of hyperphosphorylated tau protein [2]. These large aggregates are formed through a process of protein misfolding, aggregation, and deposition that begins with the formation of small soluble oligomers, now thought to be the most toxic species of both Aβ and tau [3, 4]. Compelling evidence supports the hypothesis that soluble oligomers of both AβO and tau (TauO) can target synapses and induce their dysfunction to cause the clinical onset and progression of AD [3, 5, 6]. Both AβO and TauO have been found in synaptic terminals (synaptosomes) isolated from AD brains [7, 8]. These findings spurred the concept of AD as a synaptic disease [9, 10]. Numerous in vitro and in vivo studies reported detrimental impacts of AβO and TauO on synaptic plasticity and memory formation, even before the overt appearance of Aβ plaques or tau tangles [11–15]. The mechanisms underlying these phenomena remain poorly understood. Notably, while both AβO and TauO can individually affect synaptic function, they can also act synergistically. Low concentrations of AβO and TauO that would not normally perturb synaptic function effectively suppress long-term potentiation (LTP) and impair memory function when administered together [13]. The colocalization of AβO and TauO at the synaptosomes isolated from AD brains has been observed [7]. Some studies showed that AβO and TauO impair synaptic plasticity and memory independently [16, 17], while others reported that AβO acts upstream of TauO to drive AD pathology [8, 18, 19].

Synaptic dysfunction and associated memory deficits are important contributors to dementia in AD, and therapeutic approaches to prevent these deficits have the potential to prevent or reverse progression of cognitive decline. Recent partial failures of Aβ-directed therapeutics in multi-center clinical trials [2] extended the interest onto tau, which may be the primary synaptotoxic element during late stages of AD. Attention is currently focused on the development of tau-directed therapies for clinical AD [3, 20, 21], but the mechanisms by which tau may drive synaptic dysfunction at later disease stages remain unclear. With all this evidence in mind, here we investigated the synaptic binding dynamics of both AβO and TauO using synaptosomes isolated from human and wild type mouse brains, wild type mouse brain slices, mouse cortical primary neurons, and 3xTgAD brains and report that TauO can outcompete and supersede AβO at the synapse. This suggests that, as the disease progresses TauO accumulate in the brain overcoming AβO at the synapse, thus becoming the most prevalent and toxic species supporting the concept of tau as an important therapeutic target [20, 21].

Methods

Human subjects and autopsy of brain tissues

Postmortem frozen brain tissues were obtained from the Oregon Brain Bank at Oregon Health and Science University (OHSU; Portland, OR, USA). Donor subjects of either sex were enrolled and clinically evaluated in studies at the National Institutes of Health (NIH)-sponsored Layton Aging and AD Center (ADC) at OHSU, in accordance with protocols approved by the OHSU Institutional Review Board (IRB). Informed consent was obtained from all participants prior to their enrolment in brain aging studies at the ADC; each subject received annual neurological and neuropsychological evaluations, with a Clinical Dementia Rating assigned by an experienced clinician. A neuropathological assessment was performed...
at autopsy in compliance with IRB-approved protocols. A neuropathologist scored autopsy brain tissue for Aβ plaques and neurofibrillary tangles according to standardized CERAD (Consortium to Establish a Registry for AD) criteria and Braak staging [22]. The tissues used in this study were from subjects classified as controls, because they had normal cognitive examination results (Mini-Mental State Examination scores 0–30) [23]. Donor subject samples were de-identified by the ADC prior to shipment to the University of Texas Medical Branch (UTMB), so no approval was required from the UTMB IRB under CFR §46.101(a)(1). The cases used in this study are described in Supplementary Table 1 (Additional file 1).

**Animals**

Wild-type 11–13-week-old male and female mice (C57BL/6J *Mus musculus*-Cat# JAX:000664, RRID: IMSR JAX:000664) and 9 male 3xTgAD mice (B6.Cg-Tg (APPSwe,tauP301L)1L fj Psen1tm1Mpm/2J Mus musculus-Cat# JAX:033930) were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). Health care was provided by the animal care specialists under supervision of the facility manager. Animal colony care and maintenance were provided daily to ensure a safe, healthy environment. Each animal was used under a protocol approved by UTMB’s Institutional Animal Care and Use Committee, ensuring that the animals experienced the minimal amount of pain/discomfort. All animals were housed under USDA standards (12:12 h light/dark cycle, ad libitum food and water) at the UTMB vivarium.

**Synaptosome isolation**

The synaptosomal fraction containing both pre- and postsynaptic components was isolated using a well-established method developed in our laboratory [24–26]. Briefly, we lysed snap frozen hippocampus (HP) and frontal cortex (FC) tissue from mouse and cognitively intact elderly human brains using SynPER lysis buffer (Thermo Fisher Scientific, Waltham, MA, USA) with 1% protease and phosphatase cocktail inhibitors. The brain homogenates were centrifuged at 12,000 × *g* for 10 min at 4 °C. The supernatants (containing the synaptosomes) were collected and centrifuged at 15,000 × *g* for 20 min at 4 °C. The synaptosomal pellets were resuspended in HEPES-buffered Krebs-like (HBK) buffer (143.3 mM NaCl, 4.75 mM KCl, 1.2 mM MgSO4·7H2O, 1.2 mM CaCl2, 20.1 mM HEPES, 0.1 mM NaH2PO4, and 10.3 mM D-glucose, pH 7.4). Finally, 0.5% of Pluronic F-68 non-ionic surfactant (cat# 24040-032, lot# 2275337; Thermo Fisher Scientific) was added to prevent synaptosome aggregation as previously described [27]. The quality and concentration (synaptosomes/µl) of isolated synaptosomes was routinely verified by flow cytometry and electron microscopy as we previously reported [24]. Sample processing for the ultrastructure, flow cytometry, and protein analyses are described in detail in the Supplementary Methods (Additional file 1).

**AβO preparation**

Human Aβ1–42 peptide was purchased from Department of Biophysics and Biochemistry, Harvard University (Cambridge, MA, USA), and AβO were prepared from lyophilized synthetic Aβ alioquots as previously described [28]. Briefly, 0.3 mg of lyophilized Aβ were dissolved in 200 µl of 1,1,1,3,3,3-hexafluoro-2-propanol (HFP) and allowed to incubate at room temperature for 10–20 min. Then, 700 µl of double-deionized water was added, and the sample was magnetically stirred in a fume hood for 48 h at room temperature (RT). A cap with four holes was placed on the tube containing the sample to allow HFP evaporation. The obtained AβO were aliquoted, frozen at –80 °C, and used within 3 months of preparation. Flow cytometry analysis of AβO binding to synaptosomes was performed using AβO spiked with HyLite Fluor 647-tagged Aβ (cat# AS-64161; AnaSpec Inc., Fremont, CA, USA). These AβO (AβO647) were prepared by adding 7 µl of tagged Aβ to the HFP-Aβ mixture prior to AβO formation. Oligomeric preparation quality was checked by western blot analysis using the AβO-specific 6E10 antibody (cat# 803002; BioLegend, San Diego, CA, USA). AβO have been well characterized by our group and others [10, 29–32].

**TauO preparation**

Prepared recombinant TauO were provided by Dr. Rakez Kayed’s laboratory. They were produced and characterized following established and published protocols [33, 34] and labeled (TauO488) as previously described [35–37]. Briefly, 1 mg of Alexa Fluor™ 488 NHS Ester Succinimidyl Ester (cat# A20000, Thermo Fisher Scientific) was dissolved in 0.1 M sodium bicarbonate to a final concentration 1 mg/ml, pH 8.3. The dye was then incubated with TauO in a 1:4 (w/w) ratio, rotating overnight at 4 °C on an orbital shaker. The following day, the solution was centrifuged (30 min, 15,000 × *g*) using 10-kDa Amicon Ultra-0.5 ml Centrifugal Filter Units (cat# UFC501024; EMD Millipore, Burlington, MA, USA) to remove unbound dye. TauO were then washed with 1 × phosphate-buffered saline (PBS) until the flow-through solution was clear. The filter compartment was then flipped and centrifuged to collect the concentrate (2 min, 1000 × *g*). Oligomer concentrations were then quantified with the Pierce™ BCA Protein Assay Kit (cat# 23227,
Thermo Fisher Scientific) and used for flow cytometry and immunofluorescence analyses.

**α-Sinuclein oligomer (α-synO) preparation**

Prepared recombinant α-synO were provided by Dr. Rakez Kayed’s laboratory. They were produced and characterized following established and published protocols [38, 39]. Briefly, an aliquot of lyophilized α-syn protein was dissolved in 280 µl of 1,1,1,3,3,3-hexafluoro-2-propanol (HFP) and allowed to incubate at room temperature (RT) for 10–20 min. Double-deionized water was added to this solution to make the final concentration 0.7 µg/µl. The resulting solution was then magnetically stirred in a fume hood for 48 h inside the fume hood at RT closed with a cap with holes to allow the evaporation of HFP.

**AβO and TauO binding challenge to synaptosomes**

Synaptosomes were treated with AβO and/or TauO for binding challenges, and the binding percentages were evaluated with flow cytometry. After assessing that the binding of AβO and/or TauO was comparable among the single human cases (Supplementary method 2), we decided to pool together an equal number of synaptosomes isolated from each subject for practical purpose. We incubated 2 million of synaptosomes for 1 h at RT without oligomers (control) as well as with AβO tagged with HyLite Fluor 647 or/and TauO tagged with Alexa Fluor™ 488 NHS Ester (Thermo Fisher Scientific) at concentrations of 0–10–20–50–100 µM. Synaptosomes were then pelleted, washed three times with HBK buffer, and resuspended in HBK. Oligomer fluorescence positivity was acquired by a Guava EasyCyte 8 flow cytometer (EMD Millipore) and analyzed using Incyte software (EMD Millipore).

**AβO and TauO oligomers binding challenge to mouse brain slices**

For this set of experiments, 3–4-month-old C57BL/6J mice were euthanized with deep isoflurane anesthesia followed by cervical dislocation, and the brains were immediately collected and sliced using a Compresstome VF-300 (Precisionary Instruments, Greenville, NC, USA) in N-methyl-D-glucamine–artificial cerebrospinal fluid (NMDG–aCSF) buffer (93 mM NMDG, 2.5 mM KCl, 1.2 mM NaH2PO4, 30 mM NaHCO3, 20 mM HEPES, 25 mM glucose, 5 mM sodium ascorbate, 2 mM thiourea, 3 mM sodium pyruvate, 2 mM MgSO4·7H2O, 2 mM CaCl2·2H2O, 12 N-Acetyl-l-Cysteine). For oligomer challenges, the slices were incubated for 1 h at RT with AβO and/or TauO at concentrations of 0–0.05–0.5–1–2.5 µM. After treatment, synaptosomes were isolated, pelleted, washed three times with HBK buffer, and resuspended in HBK buffer. Oligomer fluorescence positivity of synaptosomes was measured as described above.

**Proteinase K digestion**

Following the challenge experiments, synaptosomes were digested with 1 mg/ml of proteinase K (PK; cat# 70663-4, lot# 3018798; EMD Millipore) for 30 min at 37 °C (1 mg of PK is the equivalent of 30 mAU, where AU is an Anson unit that represents the amount of enzyme that liberates 1.0 µmol (181 µg) of tyrosine from casein per min at pH 7.5 at 37 °C). The remaining oligomer binding positivity was measured by a Guava EasyCyte flow cytometer (EMD Millipore) and analyzed using Incyte software (EMD Millipore). For pretreatment experiments, synaptosomes were digested with 1 mg/ml of PK (cat# 70663-4, lot# 3018798; EMD Millipore) for 30 min at 37 °C prior to challenge with labeled AβO and TauO. Binding was measured as for the other experiments.

**Western blot**

Synaptosomes were treated with AβO and/or TauO for binding challenges, and the binding percentages were evaluated by western blotting analyses. We pooled together an equal number of synaptosomes isolated from each sample. We incubated 2 million of synaptosomes for 1 h at RT without oligomers (control) as well as with AβO and/or TauO at concentrations of 0–2.5–10 µM. Synaptosomes were washed three times with HBK buffer, and the pellets were lysed with 1× radioimmunoprecipitation assay buffer (RIPA buffer) with 1% protease and phosphatase cocktail inhibitors. Tricine sample buffer (Thermo Fisher Scientific) was added to the total proteins derived from AβO-treated synaptosomes to a final concentration of 1×. Then, proteins were loaded in a 16% Novex Tricine gels (Thermo Fisher Scientific) followed by 45 min transfer to Amersham Protran nitrocellulose transfer membranes (GE Healthcare-Life Sciences, Chicago, IL, USA) at 85 V at 4 °C. The use of tricine sample buffer and gel is well recommended for the detection of low molecular weight proteins. Lithium dodecyl sulfate sample buffer (Thermo Fisher Scientific) was added to the total proteins derived from TauO-treated synaptosomes to a final concentration of 1×. Then, proteins were loaded in a 12% NuPAGE Bis–Tris gels (Thermo Fisher Scientific) followed by 1 h transfer to Amersham Protran nitrocellulose transfer membranes (GE Healthcare-Life Sciences).
at 95 V at 4 ºC. The membranes were blocked using Odyssey blocking buffer (LI-COR, Lincoln, NE, USA) for 1 h at RT and incubated at 4 ºC overnight with the anti-Aβ antibody (6E10, cat# 803002; RRID:AB_2564654; 1:1000 dilution; BioLegend) or the anti-tau antibody (Tau5; cat# 806402; RRID:AB_2564706; 1:1000 dilution; BioLegend) and 1 h at RT with the anti-synaptophysin (SYPH) antibody (cat# ab8049; RRID:AB_2198854; 1:10,000 diluted; Abcam, Cambridge, UK).

All primary antibodies were prepared in a 1:1 solution of 1 × Tris-buffered saline solution with Tween (TBST) and Odyssey blocking buffer. After incubation, the membranes were washed three times with 1 × TBST (10 min each) and incubated 1 h with LI-COR secondary antibodies diluted at 1:10,000 in 1 × TBST-Odyssey blocking buffer at RT. The membranes were again washed three times for 10 min each. Western blots were imaged using an LI-COR Odyssey infrared imaging system, application software version 3.0.30. The density of immunoreactive oligomeric bands (selected all together) were measured using ImageJ FIJI software (https://imagej.nih.gov/ij, NIH, Bethesda, MD, USA).

**Primary neuron isolation**

Primary cortical neuronal cultures were prepared and maintained as described previously [37]. Briefly, cortical neurons were isolated from C57BL/6 mice during embryonic days 16–18 by gentle trituration by a fire-polished glass pasteur pipet with Accutase® solution (cat# A6964, Sigma, St. Louis, MO, USA). Dissociated cells were plated at a density of 5 × 10⁵ cells/ml in Ibidi µ-Slide 8 Well Glass Bottom (cat# 80827; Ibidi GmbH, Martinsried, Germany) containing high-glucose Dulbecco’s Modified Eagle’s Medium (cat# 10–013-CV; Corning, Corning, NY, USA) with 2% B-27 Plus supplement (cat# A3582801; Gibco/Thermo Fisher Scientific), 10,000 U/ml penicillin, 10,000 µg/ml streptomycin, and 25 µg/ml amphotericin B (cat# 15240062, Gibco/Thermo Fisher Scientific). After 2 h, plating medium was removed from Is and replenished with neurobasal medium (cat# 12348019, Gibco/Thermo Fisher Scientific) plus 2% B-27 Plus, 0.5 mM GlutaMax (cat# 35050-061, Gibco/Thermo Fisher Scientific), 10,000 U/ml penicillin, 10,000 µg/ml streptomycin, and 25 µg/ml amphotericin B supplement. Half of the medium was changed every 3–5 days. Cells on days 7–10 in vitro were used for all experiments.

**Primary neuron treatment and immunofluorescence**

Cultured neurons were exposed to AβO647 and TauO488 at concentrations of 2.5 µM at 37 ºC for 30 min. After treatment, oligomer-containing media were removed, and cells were washed three times with 1 × PBS (5 min each). Cells were fixed with 300 µl of 4% paraformaldehyde (PFA)/PBS for 15 min at RT. Cells were then permeabilized in 300 µl of 0.25% Triton X-100 in PBS (PBST) for 10 min at RT and then washed three times in 1 × PBS (5 min each). Blocking was done in 300 µl of 5% normal goat serum/5% bovine serum albumin (BSA) in PBST for 1.5–2 h. Primary antibodies were diluted 1:500 in 5% BSA/PBST for overnight incubation at 4 ºC (microtubule-associated protein 2 [MAP2] antibody, cat# MAP2; Aves Labs, Tigard, OR, USA; postsynaptic density-95 [PSD95] antibody, cat# ab13552, RRID:AB 300453, Abcam). After primary antibody incubation, the cells were three times in PBST (10 min each). Secondary antibodies from Thermo Fisher Scientific were diluted in 5% BSA/PBST for 2 h at RT (Goat anti-Rat IgG (H + L) Cross-Adsorbed Secondary Antibody, Alexa Fluor 594, cat# A11007, RRID:AB_141374; 1:400 diluted; Goat anti-Chicken IgY (H + L) Cross-Adsorbed Secondary Antibody, Alexa Fluor Plus 405, cat# A48260; 1:250 diluted). Total number of PSD95 puncta has been calculated using ImageJ FIJI (NIH) Software with analyze particle plugin after thresholding neuronal projections 30 µm in length (n = 18 per group). Synaptic AβO and TauO has been evaluated as oligomers co-localizing with PSD95 puncta. Using colocalization threshold plugin function in ImageJ FIJI we measured the synaptic density of AβO and TauO co-localizing with PSD95. The grade of synapses/oligomers association, in each study group, has been calculated with the following ratio: colocalizing AβO/PSD95 puncta divided by the total number of PSD95 puncta in the same projection. Same method has been used for synaptic TauO in neuronal projections.

**Intracerebroventricular (ICV) injections**

16-month-old 3xTgAD mice were anesthetized with isoflurane and subjected to ICV injections using the freehand injection method previously described [40, 41]. Briefly, a 29-gauge needle, firmly held with hemostatic forceps to leave 4.5 mm of the needle tip exposed, was connected to a 25 µl Hamilton syringe via 0.38 mm polyethylene tubing. Infusions were performed at the rate of 3 µl/min for a total volume of 3 µl, using an electronic programmable microinfuser (Harvard Apparatus). Mice were ICV injected with 3ul of 0.55 µM of either AβO or TauO. After ICV injection, the needle was left in place for 2 min, while the mouse was allowed to recover lying on a heated pad under warm light. 24 h after ICV injection of oligomers or PBS, mice were euthanized and the brains were removed, dissected, snap frozen on dry ice, and stored at −80 ºC. Then, we isolated synaptosomes from hippocampus and frontal cortex and subjected the protein extracts to western blot analysis to evaluate the effects of the ICV injected AβO and TauO.
on endogenous TauO and AβO, respectively, in comparison with the control mice (ICV with PBS).

Fluorescence-assisted single synaptosome long-term potentiation

Fluorescence-assisted single synaptosome long-term potentiation (FASS-LTP) is a chemically induced LTP technique (cLTP) focused on the insertion of the glutamatergic α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) GluA1 into the postsynaptic surface, which is an essential event for synaptic transmission potentiation. FASS-LTP identifies potentiated synapses by tracking the surface expression in size-gated, glycine-activated synaptosomes of GluA1 and neurexin-1β (Nrx1β), a presynaptic adhesion molecule stabilized at the membrane surface by synaptic activity. FASS-LTP uses antibodies specific for extracellular epitopes on GluA1 and Nrx1β and we measured GluR1 + Nrx1β + double-labeled synaptosomes to ensure the analysis of only intact synaptosomes that contain both presynaptic and postsynaptic elements. FASS-LTP experiments were conducted as previously described [42–44]. Briefly, 5 × 10⁶ synaptosomes were suspended in separate tubes containing different solutions. Tube E contained 200 µl of extracellular solution (20 mM NaCl, 3 mM KCl, 2 mM CaCl₂, 2 mM MgCl₂, 15 mM glucose, and 15 mM HEPES, pH 7.4), tube B contained 200 µl of basal solution (20 mM NaCl, 3 mM KCl, 2 mM CaCl₂, 2 mM MgCl₂, 15 mM glucose, and 15 mM HEPES, pH 7.4), and tube C contained 200 µl of cLTP solution (150 mM NaCl, 5 mM KCl, 2 mM CaCl₂, 30 mM glucose, and 10 mM HEPES, pH 7.4). Synaptosomes in extracellular solution were used to determine the basal levels of potentiated synaptosomes. All tubes were incubated at RT on a slowly oscillating shaker to thaw the frozen samples. For stimulation, 20 µl of 5 mM glycine (N-methyl D-aspartate receptor [NMDAR] co-agonist) was added to the tube C freshly supplemented with 0.001 mM strychnine and 0.02 mM bicuculline methiodide. Equivalent amounts of extracellular solution were added to control tubes E and B. Following stimulation, synaptosomes in tube C were depolarized with 100 µl of KCl solution (50 mM NaCl, 100 mM KCl, 2 mM CaCl₂, 30 mM glucose, 10 mM HEPES, 0.5 mM glycine, 0.001 mM strychnine, 0.02 mM bicuculline) and incubated at 37 °C for 30 min. This step is based on the principle that high KCl concentrations depolarize synaptosomes to release endogenous glutamate, which further activates synaptic NMDARs in conjunction with the co-agonist glycine. Equivalent amounts of extracellular solution were added to tubes E and B and incubated along with tube C for 30 min at 37 °C. The contents in tubes E, B, and C were transferred to 15-ml centrifuge tubes. Then, 0.5 ml of ice-cold 0.1 mM EDTA–PBS solution and 4 ml of 5% blocking buffer (5% fetal bovine serum in PBS) were added to tubes E, B, and C to stop the reaction. Tubes were kept on ice and centrifuged at 2500 × g for 5 min at 4 °C, and the supernatant was discarded. The translocated AMPARs are then captured by adding to the tubes B and C. 2.5 µg/ml of the primary antibodies specific for the extracellular epitopes GluR1 (anti-GluR1 antibody, cat# ABN241, RRID:AB_2721164, EMD Millipore) and Nrx1β (cat#75-216, RRID:AB_2155531; Antibodies Incorporated, Davis, CA, USA) prepared in blocking solution. After incubation with the primary antibodies and subsequent washes with 1 × PBS, the samples were centrifuged at 2500 × g for 5 min at 4 °C. Pellets were resuspended in 100 µl of secondary antibody solution (Goat anti-Mouse IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor 647, cat#A-21236, RRID:AB_2535805; Goat anti-Rabbit IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, AlexaFluor 488, cat#A-11034, RRID:AB_2576217; both from Thermo Fisher Scientific). After 45 min of incubation at 37 °C, synaptosomes were washed twice with 1 × PBS and then centrifuged at 2500 × g for 5 min. Endogenous/nonspecific background fluorescence for each marker was determined using secondary antibody staining only in tube B containing synaptosomes maintained in external solution (37 °C, 45 min); no differences in background fluorescence were found between tubes B and C. After the second wash, pellets were resuspended in 400 µl of 2% PFA in PBS and maintained at 4 °C in the dark. Samples were acquired at Guava EasyCyte flow cytometer (EMD Millipore) and the cLTP analyzed using Incyte software (EMD Millipore) (Supplementary Fig. 7, Additional file 1).

Statistical analyses

Statistical analyses were performed using GraphPad Prism version 9.1.0 software. T test two-tailed, one-way ANOVA with Dunnett’s multiple comparison test, or two-way ANOVA with Tukey’s multiple comparison test were used to detect significant differences between groups. Data were then expressed as the mean ± SD, and for all statistical analyses p = 0.05 was considered as statistically significant.

Results

AβO and TauO binding to human synaptosomes

To evaluate synaptic sensitivity to AβO and TauO, we used flow cytometry to assess their binding to synaptosomes isolated from frozen human FC and HP. Synaptosomes were incubated with increasing concentrations of oligomers (0.5–1–2.5–5–10 µM). As shown in Fig. 1 and supplementary Fig. 1 (Additional file 1), we observed dose-dependent increases in the percentages of binding of AβO (Fig. 1a, b...
Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for...

Similar results were obtained when we incubated synaptosomes from mouse FC and HP with AβO and TauO (Supplementary Fig. 2, Additional file 1). To evaluate whether AβO and TauO were internalized or remained at the surface, we subjected the human synaptosomes to PK digestion. As shown in Fig. 1, both AβO (Fig. 1a, b gray columns) and TauO (Fig. 1c, d, gray columns) were accessible to enzymatic digestion in synaptosomes from human FC and HP, suggesting that both oligomeric species remained mostly at the external surface of the synaptosome, at least for the 60 min time frame of our experimental procedure. These data indicate that the methodology used in the present work allowed us to characterize dose dependent AβO and TauO binding at the surface of isolated human or murine synaptosomes.

AβO and TauO synaptic binding dynamics in isolated synaptosome, primary neurons and in vivo models

A: isolated synaptosomes

Synaptosomes isolated from human FC and HP were incubated with either AβO or TauO (both 2.5 µM) in the presence of increasing concentrations (0.5–10 µM) of TauO or AβO, respectively, and levels of the resulting binding was detected by flow cytometry. The percentage of AβO bound to human FC synaptosomes significantly decreased in the presence of all TauO concentrations (0.5–10 µM, Fig. 2a). Similar results were observed when AβO binding to human HP synaptosomes (Fig. 2b) was evaluated in the presence of increasing TauO concentrations (0.5–10 µM). On the other hand, TauO binding to synaptosomes isolated from human FC (Fig. 2c) and HP (Fig. 2d) was not reduced by the concomitant presence of low AβO levels (0.5–1–2.5 µM).
Notably, higher AβO concentrations (5 and 10 µM) induced a trend of increase in TauO binding to FC (significant for AβO 10 µM) and HP (significant for both AβO 5 and 10 µM) (Fig. 2d) synaptosomes. Similar results were observed in mouse synaptosomes (Supplementary Fig. 3, Additional file 1). To confirm these observations, we performed western blotting analyses on human synaptosomes post-challenged with either AβO or TauO (2.5 µM) and AβO, respectively. Our results showed that the amounts of AβO bound to human FC (Fig. 3a) and HP (Fig. 3b) synaptosomes decreased by 0.3- and 0.5-fold in the presence of TauO at 2.5 µM and 10 µM, respectively. Conversely, the amount of TauO bound to human FC (Fig. 3c) and HP (Fig. 3d) synaptosomes was not significantly affected by AβO 2.5 µM but increased by ~ five fold in the presence of 10 µM AβO. Moreover, human FC and HP synaptosomes incubated with AβO 2.5 µM in the presence of increasing concentrations (0.5–5 µM) of α-synuclein oligomers (α-synO) failed to show any reduction trend in synaptosomes positive for AβO, suggesting that the decrease in synaptic AβO binding is relatively specific to TauO (Supplementary Fig. 4a, b, Additional file 1). Furthermore, human FC and HP synaptosomes incubated with TauO 2.5 µM in the presence of increasing concentrations (0.5–5 µM) of α-synO failed to show any increase trend in synaptosomes positive for TauO, suggesting that the increase in TauO binding is relatively specific to AβO (Supplementary Fig. 4c, d, Additional file 1). To determine if this phenomenon also occurred in a system in which the cytoarchitecture of the CNS is preserved, we studied the binding dynamics of AβO and TauO in brain slices prepared from 4-month-old C57BL/6J mice (n = 14). We treated brain slices for 1 h with 0.05–0.5–1–2.5 µM of labeled AβO or TauO before preparing synaptosomes for flow cytometry to assess binding. We observed dose-dependent increases in the percentages of AβO (Fig. 4a) and TauO (Fig. 4b) binding. We also treated mouse brain slices from 10 mice with a combination of AβO (2.5 µM) and TauO (1 µM) and observed that the amount of AβO bound to synaptosomes decreased by ~ 0.5 fold in the presence of TauO 1 µM (Fig. 4c). Consistent with the data described above, the amount of synaptosome-bound TauO increased by ~ 0.5-fold in the presence of AβO 2.5 µM (Fig. 4d).
analyses on the synaptosomal protein extracts as previously described [29]. Naïve 3xTgAD mice were used as control. We collected the brain regions 24-h post-ICV injections and extracted the synaptosomal proteins from hippocampus and frontal cortex. Western blot analyses performed on synaptosomal proteins extracted from 3xTgAD mice ICV injected with TauO showed a decrease in AβO levels in both frontal cortex (Fig. 6a) and hippocampus (Fig. 6b) synaptosomes of ~0.8 and ~0.65 fold, respectively, as compared with 3xTgAD naïve mice. On the other hand, western blot analyses performed on synaptosomal protein extracted from 3xTgAD mice injected ICV with AβO showed an increase in TauO levels in both frontal cortex (Fig. 6c) and hippocampus (Fig. 6d) synaptosomes of ~2.5 and ~two fold, respectively, as compared with 3xTgAD naïve mice.

Collectively, these results show differential synaptic binding dynamics for AβO and TauO in three distinct model systems (isolated synaptosomes, in vitro primary neurons and in vivo), where TauO negatively affected the binding of AβO to synaptosomes, whereas high concentrations of AβO promoted the synaptic binding of TauO.
Effect of PK pre-treatment on AβO and TauO synaptic binding

To understand if AβO and TauO binding occur on a protein substrate, we pre-treated human FC and HP synaptosomes with 1 mg/ml of PK for 30 min at 37 °C to remove cell-surface proteins. Then we challenged the digested synaptosomes with increasing concentrations of AβO and TauO, then synaptosomes were isolated and subjected to flow cytometric analysis to evaluate the dose-dependent binding percentages of AβO and TauO. Data represent the mean ± SD; **P = 0.0077 and ****P < 0.0001 compared with synaptosomes derived from untreated mouse brain slices (biological replicates n = 14–30; independent experiments n = 5; ordinary one-way ANOVA plus Dunnett’s multiple comparisons); mouse brain slices were treated with a combination of AβO 2.5 µM and TauO 1 µM before the synaptosomes were isolated for flow cytometric analyses to evaluate the binding percentage of AβO and TauO. Data represent the mean ± SD; ****P < 0.0001 compared with brain slices challenged with AβO or TauO alone (biological replicates n = 10; independent experiments n = 2; paired t-test, two-tailed).

The other hand, the binding of TauO to PK pre-treated human FC (Fig. 7c) and HP (Fig. 7d) synaptosomes was increased by the concomitant presence of AβO (5 µM and 10 µM), similarly with what we observed in synaptosomes not pre-treated with PK. Collectively these data suggest that TauO can outcompete AβO from a protein substrate, while the ability of high AβO levels to increase synaptic TauO recruitment is related to a non-protein substrate.

TauO-induced cLTP suppression is not affected by AβO

To assess the impact of the oligomers on synaptic function, we analyzed the effects of AβO and TauO on cLTP in stimulated synaptosomes with fluorescence analysis of single-synapse long-term potentiation (FASS-LTP) [42–44] (Fig. 8 and Supplementary Fig. 8). Human FC and HP synaptosomes were challenged with AβO and/or TauO (both 0.5 µM) prior to FASS-LTP analyses. AβO did not affect cLTP in human FC synaptosomes (Fig. 8a) but suppressed it in human HP synaptosomes (Fig. 8b). Notably, TauO treatment suppressed cLTP in HP synaptosomes and showed a trend of suppression in FC synaptosomes. Consistent with the binding results, these data show that TauO-induced cLTP suppression was not affected by the concomitant presence of AβO in human FC or HP synaptosomes.

Discussion

This study investigated synaptic binding dynamics for AβO and TauO to determine the level of interaction between these oligomer species at the synapses, yielding seven main findings. (1) Experiments assessing dose-dependent AβO and TauO binding to human FC and HP synaptosomes demonstrated that binding was mostly limited to the synapse surface within the 1h time frame of our experimental procedure. (2) Flow cytometry and western blotting studies demonstrated that the amount of AβO bound to FC and HP synaptosomes significantly decreased in presence of TauO. Although lower levels of AβO did not alter TauO binding, higher AβO concentrations resulted in increased TauO binding to human synapses. (3) These findings were confirmed in mouse brain slices with intact neuronal architecture. (4) Immunofluorescence analyses of mouse primary cortical neurons treated with AβO and/or TauO fully supported these data. (5) Western blot analyses of synaptosomal proteins derived from hippocampus and frontal cortex of 3xTgAD mice injected ICV with AβO and TauO reinforced these findings in vivo. (6) Pre-treatment with PK showed that the effect of TauO in reducing AβO synaptic binding was lost after the depletion of synaptosome surface proteins; on the other hand, the effect of AβO in increasing TauO synaptic
binding was not affected. (7) Functional FASS-LTP studies revealed that TauO-induced cLTP suppression was not affected by the presence of AβO. Taken together, our results provide deeper insight into the interplay between AβO and TauO that contributes to synaptic dysfunction, which is the basis of the cognitive decline in AD [3, 5]. This study is focused on hippocampus and frontal cortex which are considered vulnerable brain regions to AD. We aim to study in the future less AD vulnerable brain regions, such as cerebellum and primary sensory cortex, to identify possible difference in AβO and TauO synaptic binding dynamics.

Synaptic dysfunction, neuronal death, and subsequent memory loss are likely due to cross talk between AβO and TauO [3, 7, 45, 46]. This underscores the importance of clarifying whether AβO and TauO act independently, in tandem, or synergistically. Some studies reported that AβO and TauO individually contribute to the characteristic AD impairment of synaptic plasticity and subsequent memory dysfunction [17, 18, 47, 48], while others showed that prior AβO accumulation is necessary for TauO-induced neuronal alterations [3, 8, 16, 19]. Moreover, one study supports the hypothesis that tau is an important mediator of AβO-induced neurodegeneration in AD [49]. An electrophysiological
investigation by Fa et al. concluded that simultaneous suppression of hippocampal Schaffer collateral high-frequency stimulation LTP and memory impairment could be induced by low concentrations of AβO and TauO that do not normally perturb synaptic function, suggesting that the two species synergistically exert their effects [13]. A 2019 report found that the neuronal impact of TauO dominated over AβO in several in vivo models [50]. Here we provide the first evidence of differential binding dynamics for AβO and TauO at human synapses, where TauO seems to overcome AβO effects, while progressive increases in AβO reinforce the effects of TauO. This latter phenomenon was demonstrated by increased amounts of TauO at human synapses promoted by AβO in a dose-dependent manner. These events were confirmed in mouse synapses derived from mouse brain slices, mouse brains post-ICV injection with either AβO or TauO, and cortical primary neurons. AβO are unique to AD and have not been described in other tauopathies [51]. Based on this and the findings described here, it is prudent to speculate that the differential temporal appearance/prevalence of AβO and TauO in AD may not be incidental. A recent investigation of how AβO uniquely seeds TauO assembly found that 100–200 nM of AβO facilitated TauO seeding [52]. Here we show that AβO increased the amount of TauO that bound to human synaptosomes. This phenomenon was also observed in PK pre-treated synaptosomes suggesting that in the absence of surface proteins AβO was still able to recruit TauO at the human synapses. Given the reported
Fig. 7 Effects of PK pretreatment of human FC and HP synaptosomes on AβO/TauO binding dynamics. The surface protein component of human synaptosomes was digested with 1 mg/ml PK before the synaptosomes were challenged with AβO and/or TauO, and the resulting binding was detected by flow cytometric analysis. CTR, synaptosomes not PK pre-treated, pre-PK, synaptosomes PK pre-treated. Binding dynamics of AβO 2.5 µM to human a FC and b HP synaptosomes in the presence of increasing concentrations of TauO (2.5 and 5 µM); Data represent the mean ± SD; **P<0.0001 compared with control synaptosomes (challenged with AβO and TauO alone) (biological replicates n=5–6; independent experiments n=3; two-way ANOVA plus Tukey’s multiple comparison test). Binding dynamics of TauO 2.5 µM to human c FC and d HP synaptosomes in the presence of increasing concentrations of AβO (5 and 10 µM). Data represent the mean ± SD; *P=0.05, **P=0.0083 (d—CTR samples) and ***P=0.0015 (d—PK samples), and ****P<0.0001 compared with control synaptosomes (challenged with AβO and TauO alone) (biological replicates n=5–6; independent experiments n=3; two-way ANOVA plus Tukey’s multiple comparison test).

Fig. 8 Impact of AβO and TauO on physiological synaptic transmission of human synapses. FASS-LTP identifies potentiated synapses by tracking GluA1 and Nrx1β surface expression in size-gated synaptosomes. Percentages of GluA1+Nrx1β+ size-gated synaptosomes isolated from human a FC and b HP post-challenged with AβO and/or TauO 0.5 µM. Data represent the mean±SEM; *P=0.05, **P=0.0088 (b TauO vs CTR) and ***P=0.0065 (b AβO+TauO vs CTR) and ****P<0.0001 compared with the basal levels (biological replicates n=5–6; independent experiments n=3; ordinary one-way ANOVA plus Dunnett’s multiple comparison test).
Conclusions

In conclusion, these findings suggest a link between the temporal occurrence of AβO and TauO and the progression of AD, with direct implications for how synaptic disruption driven by the binding of these oligomers underlies dementia pathogenesis in a differential and yet interactive way. Our work highlights the importance of developing therapeutic approaches that target TauO; such treatments could be beneficial for both late-stage AD and other tauopathies.

Supplementary Information The online version contains supplementary material available at https://doi.org/10.1007/s00018-022-04255-9.

Acknowledgements This work was supported by NIH/NIA R01AG069433, R01AG060718 and R56063405 to GT. We acknowledge Dr. Randall Woltjer from Oregon Brain Bank at Oregon Health and Science University (OHSU) for post-mortem tissues. We acknowledge Dr. Randall Woltjer from Oregon Brain Bank at Oregon Health and Science University (OHSU) for post-mortem tissues. We also wish to acknowledge Dr. Nicha Puangmalai, PhD for providing technical support with primary neurons culture, Dr. Nemil Bhatt for providing the preformed tau oligomers, Dr. Jutapit Guptrakar for performing the IVC injections in the 3xTgAD mice, Dr. Efstathia Polychronopoulou for supporting with statistical analyses, and Lindsay Reese, PhD (SciReviser) for text editing.

Author contributions MM and GT designed research; MM, AF, MM, and CN performed research; MM, GT, BK, and RK analyzed and interpreted the data; MM and GT wrote the paper. All authors reviewed the manuscript, provided revisions if necessary, and agreed to publication. All authors read and approved the final manuscript.

Funding This work was supported by Supported by NIH/NIA R01AG069433, R01AG060718 and R56063405 to GT.

Availability of data and materials All data generated or analyzed during this study are included in this publication and/or are available from the corresponding author on reasonable request.

Declarations

Conflict of interest The authors declare that they have no competing interests.

Ethics approval The data reproduced in this article utilized human tissue that was procured via the Oregon Brain Bank at Oregon Health and Science University (OHSU; Portland, OR, USA), which provides de-identified samples. This study was reviewed and deemed exempt by the OHSU Institutional Review Board. The BioBank protocols are in accordance with the ethical standards of our institution and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Consent for publication Not applicable.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Fabiani C, Antollini SS (2019) Alzheimer’s disease as a membrane disorder: Spatial cross-talk among beta-amyloid peptides, nicotinic acetylcholine receptors and lipid rafts. Front Cell Neurosci 13(July):1–28
2. Tiwari S, Venkata A, Kaushik A, Adriana Y, Nair M (2019) Alzheimer’s disease diagnostics and therapeutics market. Int J Nanomedicine 2019(14):5541–5554
3. Spires-Jones TL, Hyman BT (2014) The intersection of amyloid beta and tau at synapses in Alzheimer’s disease. Neuron 82(4):756–771. https://doi.org/10.1016/j.neuron.2014.05.004
4. Ashraf G, Greig N, Khan T, Hassan I, Tabrez S, Shakil S et al (2014) Protein misfolding and aggregation in Alzheimer’s disease and type 2 diabetes mellitus. CNS Neurol Disord - Drug Targets 13(7):1280–1293
5. John A, Reddy PH (2021) Synaptic basis of Alzheimer’s disease: focus on synaptic amyloid beta, P-tau and mitochondria. Ageing Res Rev 65(July 2020):101208. https://doi.org/10.1016/j.arr.2020.101208
6. Lacor PN, Buniel MC, Chang L, Fernandez SJ, Gong Y, Viola KL et al (2004) Synaptic targeting by Alzheimer’s-related amyloid β oligomers. J Neurosci 24(45):10191–10200
7. Fein JA, Sokolow S, Miller CA, Vinters HV, Yang F, Cole GM et al (2008) Co-localization of amyloid beta and tau pathology in Alzheimer’s disease synaptosomes. Am J Pathol 172(6):1683–1692
8. Bilousova T, Miller CA, Poon WW, Vinters HV, Corrada M, Kawas C et al (2016) Synaptic amyloid-β oligomers precede p-tau and differentiate high pathology control cases. Am J Pathol 186(1):185–198. https://doi.org/10.1016/j.ajpath.2015.09.018
9. Jackson J, Jambrina E, Li J, Marston H, Menzies F, Phillips K et al (2019) Targeting the synapse in Alzheimer’s disease. Front Neuosci 13(July):1–8
10. Micci MA, Krishnan B, Bishop E, Zhang WR, Guptrakar J, Grant A et al (2019) Hippocampal stem cells promotes synaptic resistance to the dysfunctional impact of amyloid beta oligomers via secreted exosomes. Mol Neurodegener 14(1):1–22
11. Gulisano W, Maugeti D, Baltrons MA, Mauro F (2018) Role of amyloid-β and tau proteins in Alzheimer’s disease: confuting the amyloid cascade. J Alzheimer’s Dis 64:S611–S631
Aβ/tau oligomer interplay at human synapses supports shifting therapeutic targets for...

12. Berger Z, Roder H, Hanna A, Carlson A, Rangachari V, Yue M et al (2007) Accumulation of pathological tau species and memory loss in a conditional model of tauopathy. J Neurosci 27(14):3650–3662

13. Fà M, Puzzo D, Piacentini R, Staniszewski A, Zhang H, Baltrons MA et al (2015) Extracellular tau oligomers produce an immediate impairment of LTP and memory. Sci Rep 6:1–15

14. Gerson J, Castillo-Carranza DL, Sengupta U, Bodani R, Prough DS, DeWeit DS et al (2016) Tau oligomers derived from traumatic brain injury cause cognitive impairment and accelerate onset of pathology in htau mice. J Neurotrauma 33(22):2034–2043

15. Lasagna-Reeves CA, Castillo-Carranza DL, Sengupta U, Clós AL, Jackson GR, Kayed R (2011) Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Mol Neurodegener 6:39

16. Jin M, Sheppardson N, Yang T, Chen G, Walsh D, Selkoe DJ (2011) Soluble amyloid β-protein dimers isolated from Alzheimer cortex directly induce Tau hyperphosphorylation and neuritic degeneration. Proc Natl Acad Sci USA 108(14):5819–5824

17. Qu X, Yuan FN, Corona C, Pasini S, Pero ME, Gundersen GG et al (2017) Stabilization of dynamic microtubules by mDia1 drives Tau-dependent Aβ(1–42) synaptotrophy. J Cell Biol 216(10):3161–3178

18. Roberson ED, Scearce-Levie K, Palop JJ, Yan F, Cheng IH, Wu T et al (2007) Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer’s disease mouse model. Science 316(5825):750–754

19. Shankar GM, Li S, Mehta TH, Garcia-Munoz A, Sheppardson NE, Smith Le et al (2008) Amyloid-beta protein dimers isolated directly from Alzheimer’s brains impair synaptic plasticity and memory. Nat Med 14(8):837–842

20. Soeda Y, Takashima A (2020) New insights into drug discovery targeting tau protein. Front Mol Neurosci 13(December):1–24

21. VandeVrede L, Boxer AL, Polydoro M (2020) Targeting tau: clinical trials and novel therapeutic approaches. Neurosci Lett 731(February):134919. https://doi.org/10.1016/j.neulet.2020.134919

22. Braak H, Braak E (1991) Neuropathological staging of Alzheimer-related changes. Acta Neuropatholog 82:239–259

23. Fm F, Fs E (1974) MINI-MENTAL STATE a practical method for grading the cognitive state of patients for clinician. J Psychiatr Res 12:189–198

24. Franklin W, Taglialatela G (2016) A method to determine insulin resistance in synaptosomes isolated from frozen brain tissue. J Neurosci Methods 261:128–134. https://doi.org/10.1016/j.jneumeth.2016.01.006

25. Comerota MM, Krishnan B, Taglialatela G (2017) Near infrared light decreases synaptic vulnerability to amyloid beta oligomers. Sci Rep 7(1):1–11. https://doi.org/10.1038/s41598-017-15357-x

26. Franklin W, Krishnan B, Taglialatela G (2019) Chronic synaptic insulin resistance after traumatic brain injury abolishes insulin protection from amyloid beta and tau oligomer-induced synaptic dysfunction. Sci Rep 9(1):1–13

27. Gyorffy BA, Kun J, Torók G, Bulyéki É, Borhegyi Z, Gulyássy P et al (2018) Local apoptotic-like mechanisms underlie complement-mediated synaptic pruning. Proc Natl Acad Sci USA 115(24):6303–6308

28. Reese LC, Zhang WR, Dineley KT, Kayed R, Taglialatela G (2008) Selective induction of calcineurin activity and signaling by oligomeric amyloid beta. Aging Cell 7(6):824–835

29. Comerota MM, Tumurbaatar B, Krishnan B, Kayed R, Taglialatela G (2019) Near infrared light treatment reduces synaptic levels of toxic tau oligomers in two transgenic mouse models of human tauopathies. Mol Neurobiol 56(5):3341–3355

30. Fracassi A, Marcatti M, Zolochevska O, Tabor N, Woltjer R, Moreno S et al (2021) Oxidative damage and antioxidant response in frontal cortex of demented and nondemented individuals with Alzheimer’s neuropathology. J Neurosci 41(3):538–554

31. Marino C, Krishnan B, Cappello F, Taglialatela G (2019) Hsp60 protects against amyloid β oligomer synaptic toxicity via modification of toxic oligomer conformation. ACS Chem Neurosci 10(6):2858–2867

32. Zolochevska O, Taglialatela G (2020) Selected microRNAs increase synaptic resilience to the damaging binding of the Alzheimer’s disease amyloid beta oligomers. Mol Neurobiol 57(5):2232–2243

33. Gerson JE, Sengupta U, Kayed R (2017) Tau oligomers as pathogenic seeds: preparation and propagation in vitro and in vivo. Methods Mol Biol 1523:16–18

34. Sengupta U, Montalbano M, McAlllen S, Minuesa G, Kharas M, Kayed R (2018) Formation of toxic oligomeric assemblies of RNA-binding protein: Musashi in Alzheimer’s disease. Acta Neuropathol Commun 6(1):113

35. Lo Cascio F, Puangmalai N, Ellsworth A, Bucchieri F, Pace A, Palumbo Piccionello A et al (2019) Toxic tau oligomers modulated by novel curcumin derivatives. Sci Rep 9(1):1–16

36. Montalbano M, McAlllen S, Puangmalai N, Wacht N, Ellsworth A et al (2019) Tau oligomers mediate aggregation of RNA-binding proteins Musashi1 and Musashi2 in reducing Lamin alteration. Aging Cell 18(6):1–22

37. Puangmalai N, Wacht N, Montalbano M, Sengupta U, Gaikwad S, Ventura F et al (2020) Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer’s disease, progressive supranuclear palsy and dementia with Lewy bodies. Cell Death Dis. https://doi.org/10.1038/s41419-020-2503-3

38. Sengupta U, Guerrero-Muñoz MJ, Castillo-Carranza DL, Lasagna-Reeves CA, Gerson JE, Paulucci-Holthauzen AA et al (2015) Pathological interface between oligomeric alpha-synuclein and tau in synucleinopathies. Biol Psychiatry 78(10):672–683. https://doi.org/10.1016/j.biopsl.2014.12.019

39. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muñoz MJ, Jackson GR, Kayed R (2010) Preparation and characterization of neurototoxic tau oligomers. Biochemistry 49(47):10039–10041

40. Dineley KT, Kayed R, Neugebauer V, Wu Y, Zhang W, Reese LC et al (2010) Amyloid-β oligomers impair fear conditioned memory in a calcineurin-dependent fashion in mice. J Neurosci Res 88(13):2923–2933

41. Krishnan B, Kayed R, Taglialatela G (2018) Elevated phospholipase D isoform 1 in Alzheimer’s disease patients’ hippocampus: relevance to synaptic dysfunction and memory deficits. Alzheimer’s Dement Transl Res Clin Interv 4:89–102. https://doi.org/10.1016/j.trci.2018.01.002

42. Prieto GA, Snigdha S, Baglietto-Vargas D, Smith ED, Berchtold NC, Tong L et al (2015) Synapse-specific IL-1 receptor subunit reconfiguration augments vulnerability to IL-1β in the aged hippocampus. Proc Natl Acad Sci USA 112(36):E5078–E5087

43. Prieto GA, Trieu BH, Dang CT, Bilousova T, Gylys KH, Berchtold NC et al (2017) Pharmacological rescue of long-term potentiation in Alzheimer diseased synapses. J Neurosci 37(5):1197–1212

44. Singh A, Allen D, Fracassi A, Tumurbataar B, Natarajan C, Scaduto P et al (2020) Functional integrity of synapses in the central nervous system of cognitively intact individuals with high Alzheimer’s disease neuropathology is associated with absence of synaptically tagged tau. J Alzheimer’s Dis 78(4):1661–1678

45. Crimins JL, Pooler A, Polydoro M, Luebke JI, Spires-Jones TL (2013) The intersection of amyloid beta and tau in glutamatergic synaptic dysfunction and collapse in Alzheimer’s disease. Ageing Res Rev 12(3):757–763. https://doi.org/10.1016/j.arr.2013.03.002

46. Ittner LM, Götz J (2011) Amyloid-β and tau—a toxic pas de deux in Alzheimer’s disease. Nat Rev Neurosci 12(2):67–72
47. Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J et al (2010) Dendritic function of tau mediates amyloid-β toxicity in Alzheimer’s disease mouse models. Cell 142(3):387–397

48. Roberson ED, Halabisky B, Yoo JW, Yao J, Chin J, Yan F et al (2011) Amyloid-β/fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer’s disease. J Neurosci 31(2):700–711

49. Zempel H, Luedtke J, Kumar Y, Biernat J, Dawson H, Mandelkow E et al (2013) Amyloid-β oligomers induce synaptic damage via Tau-dependent microtubule severing by TTLL6 and spastin. EMBO J 32(22):2920–2937. https://doi.org/10.1038/emboj.2013.207

50. Busche MA, Wegmann S, Dujardin S, Commins C, Schiantarelli I, Klickstein N et al (2019) Tau impairs neural circuits, dominating amyloid-β effects, Alzheimer models in vivo. Nat Neurosci 22(1):57–64. https://doi.org/10.1038/s41593-018-0289-8

51. Cline EN, Bicca MA, Viola KL, Klein WL (2018) The Amyloid-β oligomer hypothesis: beginning of the third decade. J Alzheimer’s Dis 64(s1):S567-610

52. Shin WS, Di J, Cao Q, Li B, Seidler PM, Murray KA et al (2019) Amyloid-β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation. Alzheimer’s Res Ther 11(1):1–13

53. Vogel JW, Iturria-Medina Y, Strandberg OT, Smith R, Levitis E, Evans AC et al (2020) Spread of pathological tau proteins through communicating neurons in human Alzheimer’s disease. Nat Commun 11(1):2612

54. d’Errico P, Meyer-Luehmann M (2020) Mechanisms of pathogenic tau and Aβ protein spreading in Alzheimer’s disease. Front Aging Neurosci 12(August):1–10

55. Rauch JN, Luna G, Guzman E, Audouard M, Challis C, Sibih YE et al (2020) LRP1 is a master regulator of tau uptake and spread. Nature 580(7803):381–385. https://doi.org/10.1038/s41586-020-2156-5

56. Smith LM, Strittmatter SM (2017) Binding sites for amyloid-β oligomers and synaptic toxicity. Cold Spring Harb Perspect Med 7(5):af024075

57. Shinohara M, Tachibana M, Kanekiyo T, Bu G (2017) Role of LRP1 in the pathogenesis of Alzheimer’s disease: evidence from clinical and preclinical studies. J Lipid Res 58(7):1267–1281. https://doi.org/10.1194/jlr.R075796

58. Tzakis N, Holahan MR (2020) Investigation of GluA1 and GluA2 AMPA receptor subtype distribution in the hippocampus and anterior cingulate cortex of Long Evans rats during development. IBRO Rep 8(March):91–100. https://doi.org/10.1016/j.ibror.2020.03.003

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.